Literature DB >> 7584153

The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation.

M Daëron1, S Latour, O Malbec, E Espinosa, P Pina, S Pasmans, W H Fridman.   

Abstract

The cell-triggering properties of BCR, TCR and FcR depend on structurally related immunoreceptor tyrosine-based activation motifs (ITAMs). Fc gamma RIIB have no ITAM and do not trigger cell activation. When coaggregated to BCR, they inhibit B cell activation. We show here that, when coaggregated to these receptors, Fc gamma RIIB inhibit Fc epsilon RI-, Fc gamma RIIA-, and TCR-dependent cell activation. Inhibition also affected cell activation by single ITAMs, in isolated FcR or TCR subunits. The same tyrosine-based inhibitory motif (ITIM), which is highly conserved in murine and human Fc gamma RIIB and that was previously shown to inhibit BCR-dependent B cell activation, was required to regulate TCR- and FcR-dependent cell activation. Our findings endow Fc gamma RIIB, and thus IgG antibodies, with general immunoregulatory properties susceptible to act on all ITAM-containing receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584153     DOI: 10.1016/1074-7613(95)90134-5

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  94 in total

1.  Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B.

Authors:  T Uehara; M Bléry; D W Kang; C C Chen; L H Ho; G L Gartland; F T Liu; E Vivier; M D Cooper; H Kubagawa
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 2.  Mast cell regulation via paired immunoglobulin-like receptor PIR-B.

Authors:  Ching-Cheng Chen; Dong-Won Kong; Max D Cooper; Hiromi Kubagawa
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors.

Authors:  Lela Kardava; Susan Moir; Wei Wang; Jason Ho; Clarisa M Buckner; Jacqueline G Posada; Marie A O'Shea; Gregg Roby; Jenny Chen; Hae Won Sohn; Tae-Wook Chun; Susan K Pierce; Anthony S Fauci
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 4.  Tolerance: an overview and perspectives.

Authors:  Herman Waldmann
Journal:  Nat Rev Nephrol       Date:  2010-08-17       Impact factor: 28.314

Review 5.  Molecular underpinning of B-cell anergy.

Authors:  Yuval Yarkoni; Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

6.  Structural and immunologic cross-reactivity among filarial and mite tropomyosin: implications for the hygiene hypothesis.

Authors:  Helton C Santiago; Sasisekhar Bennuru; Alexis Boyd; Mark Eberhard; Thomas B Nutman
Journal:  J Allergy Clin Immunol       Date:  2010-12-24       Impact factor: 10.793

7.  Experimental infection with Trypanosoma cruzi increases the population of CD8(+), but not CD4(+), immunoglobulin G Fc receptor-positive T lymphocytes.

Authors:  Andrea Henriques-Pons; Bianca P Olivieri; Gabriel M Oliveira; Marc Daëron; Tania C de Araújo-Jorge
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

8.  Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?

Authors:  M A Martins; M L Silva; A P V Marciano; V Peruhype-Magalhães; S M Eloi-Santos; j G L Ribeiro; R Correa-Oliveira; A Homma; E G Kroon; A Teixeira-Carvalho; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 9.  The conundrum of inhibitory signaling by ITAM-containing immunoreceptors: potential molecular mechanisms.

Authors:  Paul M Waterman; John C Cambier
Journal:  FEBS Lett       Date:  2010-09-28       Impact factor: 4.124

10.  Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.

Authors:  Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.